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Background: Alpha-synuclein is a key protein implicated in the pathogenesis of Parkinson's disease (PD). It is the
main component of the Lewy bodies, a cardinal neuropathological feature in the disease. In addition, whole locus
multiplications and point mutations in the gene coding for alpha-synuclein lead to autosomal dominant
monogenic PD. Over the past decade, research on PD has impelled the development of new animal models based
on alpha-synuclein. In this context, transgenic mouse lines have failed to reproduce several hallmarks of PD,
especially the strong and progressive dopaminergic neurodegeneration over time that occurs in the patients. In
contrast, viral vector-based models in rats and non-human primates display prominent, although highly variable,
nigral dopaminergic neuron loss. However, the few studies available on viral vector-mediated overexpression of
alpha-synuclein in mice report a weak neurodegenerative process and no clear Lewy body-like pathology. To
address this issue, we performed a comprehensive comparative study of alpha-synuclein overexpression by means
of recombinant adeno-associated viral vectors serotype 2/7 (rAAV2/7) at different doses in adult mouse substantia
nigra.
Results: We noted a significant and dose-dependent alpha-synucleinopathy over time upon nigral viral
vector-mediated alpha-synuclein overexpression. We obtained a strong, progressive and dose-dependent loss of
dopaminergic neurons in the substantia nigra, reaching a maximum of 82% after 8 weeks. This effect correlated
with a reduction in tyrosine hydroxylase immunoreactivity in the striatum. Moreover, behavioural analysis revealed
significant motor impairments from 12 weeks after injection on. In addition, we detected the presence of
alpha-synuclein-positive aggregates in the remaining surviving neurons. When comparing wild-type to mutant
A53T alpha-synuclein at the same vector dose, both induced a similar degree of cell death. These data were
supported by a biochemical analysis that showed a net increase in soluble and insoluble alpha-synuclein
expression over time to the same extent for both alpha-synuclein variants.
Conclusions: In conclusion, our in vivo data provide evidence that strong and significant alpha-synuclein-induced
neuropathology and progressive dopaminergic neurodegeneration can be achieved in mouse brain by means of
rAAV2/7.
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Parkinson’s disease (PD) is a common neurodegenerative
movement disorder that affects 1% of the population aged
over 65. Clinically, PD is characterized by major motor
symptoms consisting of bradykinesia, cogwheel rigidity,
resting tremor and postural instability. The neuropatho-
logical cardinal features of the disease comprise both the
preferential loss of the dopaminergic neurons of the sub-
stantia nigra (SN) and the prevalence of large cytoplasmic
inclusions rich in alpha-synuclein (α-synuclein) protein,
named Lewy bodies (LBs), which are present in the
remaining cells [1]. In addition, whole locus duplications
and triplications and genetic single mutations (A53T,
A30P, E46K, H50Q, G51D) in the SNCA gene coding for
α-synuclein result in autosomal-dominant familial forms
of PD [2-8]. The severity of the phenotype correlates with
the SNCA genomic dosage implying that high levels of α-
synuclein can in fact trigger the neurodegenerative process
[9]. Finally, genome-wide association studies also support
this critical role for α-synuclein in the pathogenesis of PD
[10,11]. The discovery of α-synuclein both as a genetic
cause for the disease and as the major component of the
LBs in sporadic and familial cases of PD has strengthened
the link between sporadic and hereditary PD forms and
the possibility of an underlying common mechanism at
the origin of the disease.
Since α-synuclein is so tightly linked to the patho-
genesis of PD, numerous transgenic mouse lines over-
expressing wild-type (WT) or mutant α-synuclein were
developed over the past decade, aiming at replicating the
neuropathology seen in patients [12,13]. Despite the fact
that these mice have proven useful in modelling some
features of the disease such as the abnormal accumula-
tion of α-synuclein in cells, they do not display a convin-
cing progressive degeneration of the nigral dopaminergic
neurons nor a dopamine-dependent motor phenotype.
Conversely, the overexpression of α-synuclein by means of
viral vectors in rodents and non-human primates induces
a progressive dopaminergic cell loss over time as the most
prominent feature (see [14] for a review). We have pre-
viously reported the overexpression of α-synuclein in
mouse and rat brain using lentiviral vectors [15-17], but
recombinant adeno-associated viral (rAAV) vectors have
steadily gained more interest to express a gene of interest
in the brain in a controlled spatio-temporal manner be-
cause of their high titers and high tropism for dopami-
nergic cells, especially for the newer serotypes [18-22].
Viral vector-based α-synuclein rat and non-human pri-
mate models display several cardinal neuropathological
features of PD. Indeed, rAAV vector-mediated over-
expression of either WT or mutant A53T α-synuclein
induces a 20 to 80% dopaminergic cell loss in 3 to
8 weeks in rats, depending on the study and the serotype
used [23-28], and a 30 to 60% dopaminergic neuron lossat 4 months after injection in marmosets [29]. Beside the
dopaminergic cell death, rat and non-human primate
models exhibit other hallmarks of PD such as the preva-
lence of α-synuclein-positive inclusions in the SN or the
presence of a phosphorylated form of α-synuclein at serine
129 (P-S129), which is largely abundant in the LBs of PD
patients [30,31]. Although promising, these viral vector-
based α-synuclein models still suffer from a certain degree
of variability and slow progression of the phenotype, hin-
dering their value for testing novel therapeutics. To
address this, we have taken a novel vector, rAAV2/7,
which can be prepared at high titer and for which we have
shown its efficient transduction of the dopaminergic neu-
rons of the SN [32]. We have developed an improved rat
model for PD by means of rAAV2/7 vector-mediated
overexpression of A53T α-synuclein in the SN, which dis-
plays progressive and robust neurodegeneration (Van der
Perren et al., submitted). Intriguingly, the few studies with
α-synuclein rAAV vectors performed in mice until now
report either no or very limited dopaminergic neuron loss,
with a maximum of 20 to 35% at 2 to 6 months after
injection [33-38]. Furthermore, no obvious α-synuclein-
positive inclusions were detected in the surviving cell
bodies [35].
In view of the increasing number of transgenic and
knockout mice, the availability of a viral vector-based
α-synuclein mouse model would offer several interesting
scientific possibilities. Therefore, we decided to explore
whether it is possible to obtain a robust parkinsonian
phenotype in mice with α-synuclein-encoding rAAV vec-
tors. We performed a comprehensive comparative study
of 3 different vector doses of rAAV2/7-α-synuclein WT in
mouse SN and analyzed them at separate time points up
to 2 months after surgery. In addition, we compared
the overexpression of human WT and mutant A53T
α-synuclein in mouse SN delivered at the same vector
dose. We assessed the changes induced by the sustained
localized overexpression of α-synuclein in mouse SN by
means of motor behavioural tests, immunohistochemical
stainings followed by stereological quantifications, and
protein solubility analysis. We succeeded in developing a
mouse model based on rAAV2/7 vector-mediated over-
expression of α-synuclein with robust dopaminergic cell
death and α-synuclein inclusions in the SN.
Methods
rAAV vector design and production
The plasmids for the rAAV vector production were pre-
viously described [39]. These plasmids include the con-
struct for the AAV2/7 serotype, the AAV transfer
plasmid and the pAdvDeltaF6 adenoviral helper plasmid.
The transfer plasmid encoded eGFP or the human WT
or A53T α-synuclein transgene, followed by the wood-
chuck hepatitis posttranscriptional regulatory element,
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promoter.
The viral vectors were produced at the Leuven Viral
Vector Core (LVVC, http://www.kuleuven.be/molmed/
research/research_viral_vector_technology.html) from the
KU Leuven (Leuven, Belgium). Vector production and
purification were performed as described in detail else-
where [19]. The final titers for the concentrated vector
stocks ranged between 8,0E + 11 and 2,7E + 12 genome
copies per millilitre (GC/ml) as determined by quantitative
PCR.
Stereotactic surgery
Housing and handling of mice was done in compliance
with the European Communities Council Directive of 24
November 1986 (86/609/EEC) and approved by the Bio-
ethical Committee of the KU Leuven. All animals were
housed under 12/12 h light/dark cycle with access to food
and water ad libitum. Female, 8 weeks old, C57BL/6 mice
received the human WT α-synuclein rAAV2/7 vector at
different titers: 2,6E + 11 GC/ml; 4,0E + 11 GC/ml or 8,
0E + 11 GC/ml. The rAAV2/7-eGFP vector was injected
at 4,0E + 11 GC/ml or 8,0E + 11 GC/ml. The human
A53T α-synuclein rAAV2/7 vector was tested at a single
dose: 4,0E + 11 GC/ml. The animals were anaesthetized
and placed in a stereotactic head frame (Stoelting, IL,
USA). After making a midline incision of the scalp, a burr
hole was drilled in the appropriate location for the SN at
the right site of the skull. 2 μl of viral vector were injected
at a rate of 0.25 μl/min with a 30-gauge needle on a 10 μl
Hamilton syringe. The needle was left in place for an
additional 5 minutes before being slowly withdrawn from
the brain. Coordinates for mouse SN were anteroposterior
(AP) -3.1 mm and mediolateral (ML) -1.2 mm relative to
bregma, and dorsoventral (DV) -4.0 mm from the dural
surface [40].
Motor behaviour
Three groups of mice (n = 10) were injected with rAAV2/
7-eGFP (8,0E + 11 GC/ml) or human WT α-synuclein
rAAV2/7 vector (8,0E + 11 GC/ml and 4,0E + 11 GC/ml)
for behavioural evaluation in the cylinder test, the rotarod
test and the open field test.
The cylinder test, which measures asymmetry in
spontaneous forelimb use, was performed at 1, 4, 8 and
12 weeks after injection. Mice were placed individually
inside a glass cylinder (12 cm diameter, 22 cm height)
positioned in front of two vertical mirrors in order to
be able to view the mouse from all angles. No habi-
tuation of the animals to the testing cylinder was
allowed before video-recording. Video-recordings were
examined by an observer blinded to the animal’s iden-
tity. Between 20 and 30 wall touches per animal (con-
tacts with fully extended digits executed with theforelimb ipsilateral and contralateral to the lesion)
were counted.
In the rotarod test, animals were trained for 2 minutes
at a speed of 4 rpm. After this initial training, mice per-
formed 8 trials of maximum 5 minutes with increasing
speed starting from 4 rpm up to 40 rpm. This test was
performed at 14 weeks after injection and fall off time
was recorded.
In the open field test, animals were placed for 30 minutes
in the dark prior to the open field cage (50×50 cm). After
1 minute of adaptation, the next 10 minutes were video-
recorded for analysis. This test was performed at 15 weeks
after injection.
Histology
At selected time points, mice were deeply anesthetized
using an overdose of pentobarbital (Nembutal, CEVA
Santé, Belgium) and transcardially perfused with saline
followed by ice-cold 4% paraformaldehyde in phosphate-
buffered saline (PBS). 50-μm-thick coronal brain sections
were cut with a vibrating microtome (HM650V, Microm,
Germany) and stored at 4°C in 0.1% sodium azide in PBS.
Immunohistochemistry was performed under uniform
conditions on free-floating sections using antibodies raised
against α-synuclein (rabbit polyclonal, 1:5000, Millipore
5038), tyrosine hydroxylase (TH, rabbit polyclonal, 1:5000,
Millipore 152) and P-S129 α-synuclein (mouse monoclo-
nal, 1:5000, Elan Pharmaceuticals, [31,41]). Sections were
pretreated with 3% hydrogen peroxide for 10 minutes to
quench endogenous peroxidase activity and then incu-
bated overnight at room temperature in primary antibody
solution with 10% normal goat serum (DakoCytomation,
Belgium). As secondary antibody, we used biotinylated
anti-rabbit or anti-mouse IgG (1:600, DakoCytomation),
followed by incubation with streptavidin-horseradish per-
oxidase complex (1:1000, DakoCytomation). TH im-
munoreactivity was visualized using Vector SG (SK-4700,
Vector Laboratories) as chromogen; and (P-S129)
α-synuclein was visualized with 3,3-diaminobenzidine
(0,4 mg/ml, Sigma-Aldrich). After being rinsed and
mounted, the sections were cover-slipped using DPX
mounting medium (Sigma).
For fluorescent double staining, sections were rinsed
three times in PBS and incubated overnight in the dark in
PBS-0.1% Triton X-100 and 0.1% sodium azide, 10%
donkey serum and the following antibodies: chicken anti-
GFP (1:500, Aves Labs 1020), rabbit anti-α-synuclein
(1:1000, Millipore 5038), mouse anti-TH (1:1000, Millipore
MAB318), mouse anti-Neuronal Nuclei (NeuN, 1:500,
Chemicon MAB377), mouse anti-α-synuclein (1:100, Invi-
trogen LB309) and rabbit anti-Glial Fibrillary Acidic Pro-
tein (GFAP, 1:100, Dako Z0334). After rinsing, the sections
were incubated in the dark for 1 h in fluorochrome-
conjugated secondary antibodies: donkey anti-chicken
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donkey anti-mouse Alexa 555 (1:400, Molecular Probes,
Invitrogen). After being rinsed and mounted, the sections
were cover-slipped with Mowiol (Sigma).Stereological quantification and confocal microscopy
The volume of α-synuclein expression in the SN and of
TH-immunoreactive fibbers in the striatum (STR) was de-
termined by stereological volume measurements based on
the Cavalieri method as described before [42,43]. The
number of TH-, α-synuclein- and P-S129 α-synuclein-
positive cells in the SN was estimated using a random
sampling stereological counting method, the optical frac-
tionator [44], in a computerized system (StereoInvestiga-
tor; MicroBright-Field, Magdeburg, Germany). Coefficient
of error attributable to the sampling was calculated ac-
cording to Gundersen and Jensen [45]. Errors ≤0.10 were
accepted. The SN was delineated from −2.54 to −3.88 mm
posterior to bregma based on the Paxinos atlas for the
mouse brain [40]. For each animal, every third section
throughout the rostro-caudal extent of the SN and every
fourth section covering the entire extent of the STR were
incorporated to the counting procedure. The conditions
of the experiment were blinded to the investigator.
Fluorescent double immunostainings for α-synuclein or
GFP and TH, and for α-synuclein and NeuN or GFAP,
were visualized by confocal laser scanning microscopy
(Fluoview 1000, Olympus). Estimation of co-transduction
was performed based on quantifications of double-stained
cells on 4 different sections.Sequential protein extraction
After cervical dislocation, the SN were rapidly dissected
from one to two 1 mm-thick coronal sections using a
mouse brain slicer, and snap frozen in dry ice. Frozen
nigral tissues were homogenized in 5 volumes of Tris-
buffered saline (TBS, pH 7.5, 10 mM Tris, 0.15 M NaCl)
plus complete protease inhibitor (TBS+, Roche Applied
Science) using a tissue homogenizer (Ultra-Turrax; IKA
Werke, Staufen, Germany). Next, proteins were sequen-
tially extracted, slightly modified from previously pub-
lished procedures [46,47]. Shortly, samples were spun at
120,000 × g for 30 minutes at 4°C. The resulting super-
natant represented the TBS soluble fraction. The pellet
was then resuspended in TBS+ containing 1% Triton
X-100 (Sigma-Aldrich), TBS+ containing 1 M sucrose and
RIPA buffer (50 mM Tris–HCl, pH 7.4, 175 mM NaCl,
5 mM ethylenediaminetetraacetic acid [EDTA], 1% NP-40,
0.5% sodium deoxycholate, and 0.1% sodium dodecyl sul-
fate [SDS]). After a last ultra-centrifugation step, the
detergent-insoluble pellet was solubilised in 2 M urea/5%
SDS to preserve α-synuclein structures [48]. Samples were
supplemented with 10% glycerol and stored at −80°C.Western blot analysis
Protein concentration was measured using the Bradford
method (Protein Assay Dye Reagent Concentrate, Biorad,
Munich, Germany). For western blotting, 30 μg of fraction-
ated protein extracts were loaded on 12% acrylamide
gel (Serva, Heidelberg, Germany) and blotted onto a
methanol-activated PVDF membrane (Immobilon P,
Millipore Corporation, Billerica, MA, USA). Immuno-
blots were blocked in 5% dry milk in TBST buffer (TBS
plus 0.1% Tween 20) and subsequently probed with:
human specific anti-α-synuclein 15G7 (1:10, AG Scientific),
anti-α-synuclein Syn1 detecting both mouse and human α-
synuclein (1:1000, BD Bioscience), anti-P-S129 α-synuclein
(1:1000, Epitomics, 2014–1). Anti-GAPDH (1:1000, Abcam
125247) or anti-β-actin (1:10000, Sigma A5441) was used
as internal loading control. Bound antibodies were de-
tected with horseradish peroxidase-conjugated secondary
antibodies and enhanced chemiluminescence (ECL or
ECLplus, GE Healthcare) followed by exposure to hyper-
film (GE Healthcare). ImageJ software was used to deter-
mine the optical density of protein bands and all data were
analyzed for each viral vector group (n = 3) based on 3 in-
dependent blots and normalized to the expression of the
corresponding GAPDH or β-actin loading control within
line.
Statistical analysis
Statistical analysis was performed using the GraphPad
Prism 5.0 software package. Results are expressed as
means ± standard error of the mean. Statistical signifi-
cance was assessed using two-way ANOVA followed by
Bonferroni post-hoc test for intergroup comparisons
or one-way ANOVA for the behavioural tests and the
western blotting analysis. Statistical significance level was
set as follows: * if P < 0.05, ** if P < 0.01, *** if P < 0.001.
Results
Efficient transduction of dopaminergic neurons upon
rAAV2/7 vector-mediated overexpression of α-synuclein
or eGFP in mouse SN
rAAV2/7-α-synuclein WT and rAAV2/7-eGFP vectors
were stereotactically injected in mouse SN (2 μl of 8,0E +
11 GC/ml). We performed fluorescent double immunos-
tainings to assess transgene expression (Figure 1). At
5 days post-injection, widespread transgene expression
was evident in the injected side for both α-synuclein and
eGFP viral vectors (Figure 1A, C). Transgene expression
of eGFP appeared stronger than α-synuclein expression at
comparable vector doses, although this might be due
to differential sensitivities of the respective antibodies.
Co-localization of α-synuclein or GFP with the dopa-
minergic marker tyrosine hydroxylase (TH) indicated
efficient transduction of the nigral dopaminergic neu-
rons distributed throughout the SN pars compacta.
Figure 1 Efficient dopaminergic neuron transduction upon rAAV2/7 vector delivery in mouse SN. (A-B) Representative confocal images of
fluorescent double immunostainings for α-synuclein (green) and TH (red) at (A) 5 days and at (B) 8 weeks after injection of rAAV2/7-α-synuclein WT at
8,0E + 11 GC/ml. (A) At 5 days post-injection, pictures reveal extensive co-localization (merge) in the transduced region. Bottom panels are magnifications
of the overviews (upper panels). Scale bar upper panel = 200 μm and bottom panel = 50 μm. Confocal images of double immunostainings for
α-synuclein (green) and NeuN or GFAP (red) show an almost exclusive neuronal transduction. Scale bar = 100 μm. (B) At 8 weeks after injection, a clear
degeneration of the nigral dopaminergic neurons is observed upon rAAV2/7 vector-mediated α-synuclein overexpression. Dopaminergic neurons remain
widely present in the contralateral side. (C-D) Fluorescent double stainings for GFP (green) and TH (red) at (C) 5 days and at (D) 8 weeks post-injection
show that rAAV2/7-eGFP at 8,0E + 11 GC/ml does not induce any dopaminergic cell death over time. Inj: injected side; N-inj: non-injected side.
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SN were transduced by the viral vectors as assessed by
high magnification confocal imaging (Figure 1A). In
addition, double immunostaining for α-synuclein and
the neuron-specific nuclear marker NeuN clearly indi-
cated efficient transduction of neurons in the injected
area, around 95% of double-positive cells, whereas
double immunostainings for α-synuclein and the astro-
cytic marker GFAP showed an absence of co-
localization, pointing to an almost exclusive neuronal
transduction.
In order to evaluate the sustained nigral viral vector-
mediated transgene expression, we performed fluores-
cent double immunostainings at 8 weeks post-injection
(Figure 1B, D). For rAAV2/7-eGFP, we observed a stable
transgene expression and normal TH immunoreactivity
in the SN (Figure 1D). In contrast, we detected few sur-
viving α-synuclein- and TH-positive cells for rAAV2/
7-α-synuclein WT, indicative of a significant loss of both
α-synuclein- and TH-positive cells at this time point in
mouse SN (Figure 1B). The non-injected sides showed
no transgene expression (α-synuclein or GFP) or loss ofdopaminergic neurons (TH) at any time point after in-
jection of rAAV2/7-α-synuclein WT or rAAV2/7-eGFP.
rAAV2/7 vector-mediated overexpression of α-synuclein
in mouse SN causes dose-dependent progressive cell
death and α-synuclein aggregation
In order to evaluate the dose- and time-dependent effects
of α-synuclein overexpression, rAAV2/7-α-synuclein WT
vector injections were unilaterally performed in adult
mouse SN at 3 different vector titers: 2,6E + 11 GC/ml;
4,0E + 11 GC/ml and 8,0E + 11 GC/ml. Mice were perfused
for immunohistochemical analysis at 5 days, 4 weeks and
8 weeks after surgery. Staining of the nigral sections for hu-
man α-synuclein revealed widespread expression of the
transgene in the injected area after 5 days (Figure 2A-B).
In addition, we observed a progressive reduction in
α-synuclein expression over time in the injected region
for all vector doses tested, and the loss was faster and
stronger with increasing viral vector titer (Figure 2B).
A cardinal feature in the neuropathology of PD is the
presence of cytoplasmic α-synuclein-rich inclusions in the
remaining surviving neurons. Therefore, we investigated
Figure 2 rAAV2/7 vector-mediated overexpression of α-synuclein in mouse SN induces progressive cell loss and α-synuclein aggregation.
(A) Images of immunohistochemical stainings for α-synuclein showing the whole area of transduction 5 days after rAAV2/7-α-synuclein injection.
Scale bar = 500 μm. (B) Overexpression of WT α-synuclein induces a progressive and dose-dependent α-synuclein-positive cell loss over time in
the injected SN. Absence of immunoreactivity in the contralateral SN at 5 days after injection when expression was maximal. Right panels are
magnifications of the overview (left panels). Scale bars = 200 μm. N-inj: non-injected side. (C) High magnification pictures demonstrate the
presence of α-synuclein-positive aggregates (arrows) in the SN for each vector dose at 4 weeks post-injection. (D) High magnification picture of
an α-synuclein-positive cell without aggregates. Scale bars (C-D) = 5 μm. (E) Stereological quantification of the α-synuclein-positive volume in the
SN of mice injected with 3 different WT α-synuclein vector doses and a unique A53T α-synuclein vector dose after 5 days, 4 weeks and 8 weeks.
(F) Stereological quantification of the number of α-synuclein-positive cells in the SN of mice after 5 days, 4 weeks and 8 weeks. Asterisks (*) depict
significant decrease respective to 4 weeks, unless specified otherwise. 5 days 4,0E + 11 GC/ml WT/A53T: n = 3; 5 days 2,6/8,0E + 11 GC/ml WT:
n = 4; 4 weeks: n = 4; 8 weeks: n = 4.
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like aggregates in the cytoplasm. α-Synuclein-positive cells
with aggregates were visualized with high magnification
resolution imaging and selected on the presence of dark
inclusions of α-synuclein protein within the cytoplasm
and an overall dystrophic morphology, as opposed to
cells without aggregates (Figure 2C-D). At 4 weeks post-
injection, we detected α-synuclein-positive cells with
aggregates for each vector dose tested.
Next, we quantified the α-synuclein expression in the
injected SN at the different time points by means of two
stereological methods (Figure 2E-F). First, we determined
the α-synuclein-positive transduced volume in the SN
(Figure 2E). We observed a progressive decrease over time
for all viral vector doses. At 8 weeks post-injection, this
reduction in the nigral α-synuclein-positive volume wasclearly more pronounced when the viral vector dose
increased. Subsequently, we quantified the number of in-
dividual α-synuclein-positive cells in the SN and we ob-
served a similar gradual and dose-dependent decrease in
α-synuclein expression over time as observed for the
α-synuclein-positive transduced volume (Figure 2F).
In addition, we aimed at comparing the overexpression
of mutant A53T α-synuclein in mouse SN with WT
α-synuclein. For this approach, we injected rAAV2/7-α-
synuclein A53T in mouse SN at the same intermediate
viral vector titer of 4,0E + 11 GC/ml. Both viral vectors
were produced in parallel, normalized for the same GC/ml
and delivered in the same manner. We observed that
rAAV2/7-α-synuclein A53T also triggered a progressive
reduction in α-synuclein expression and the formation of
cytoplasmic α-synuclein-positive aggregates over time
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neurodegeneration was slightly stronger than for the WT
α-synuclein viral vector (Figure 2E-F).
rAAV2/7 vector-mediated overexpression of α-synuclein
induces progressive nigral and striatal dopaminergic
neurodegeneration in a dose-dependent manner
To specifically evaluate the dopaminergic neurodegenera-
tion induced by the overexpression of α-synuclein at the
different viral vector doses, we performed immunohisto-
chemical stainings for TH in the SN. As control, the
rAAV2/7-eGFP vector was tested at the highest vector
dose used in this study (8,0E + 11 GC/ml) to exclude un-
specific toxic effects due to the high viral vector titer. We
observed a progressive and significant loss of nigral dopa-
minergic neurons over time for all doses of α-synuclein
vector (Figure 3A). In contrast, the rAAV2/7-eGFP vector
did not induce any nigral dopaminergic neurodegenera-
tion in this time frame. In addition, no dopaminergic cell
loss was observed at the contralateral side at 8 weeks
post-injection when the neurodegeneration was maximal.
Next, we estimated the total number of TH-positive neu-
rons in the SN by means of unbiased stereological quanti-
fication (Figure 3C). At 5 days post-injection, no acute cell
death was observed for any of the different viral vectors.
As for the lowest α-synuclein viral vector dose tested
(2,6E + 11 GC/ml), stereological counts revealed a 19%
TH-positive neuron loss at 4 weeks after injection respec-
tive to rAAV2/7-eGFP, which increased up to 23% at
8 weeks post-injection. Nigral dopaminergic neurode-
generation was also observed for the other two WT
α-synuclein viral vector titers: from 45% at 4 weeks to 50%
at 8 weeks for the intermediate vector dose (4,0E + 11
GC/ml); and from 57% at 4 weeks to 82% at 8 weeks for
the highest dose (8,0E + 11 GC/ml). Stereological quantifi-
cation of the number of TH-positive cells in the SN
contralateral to the side of injection showed no cell death
for all conditions (Figure 3D). These results show that a
progressive dopaminergic cell death is observed over time
for all α-synuclein vector conditions, and that the degree
of dopaminergic neuron loss at a given time point posi-
tively correlates with the viral vector dose used.
Similar to the observations for the SN, immunohisto-
chemical stainings for TH in the STR revealed a gradual
decrease in TH expression over time for the 3 different
α-synuclein WT vector doses whereas the non-injected
side remained intact (Figure 3B). Next, we assessed the
degeneration of the dopaminergic nerve terminals in
the STR by stereological quantification of the striatal TH-
positive volume. At 4 weeks post-injection, stereological
counts revealed a 17% TH-positive volume reduction re-
spective to the contralateral side for the lowest vector dose
(2,6E + 11 GC/ml), that increased up to 56% at 8 weeks
post-injection (Figure 3D). The same progressive loss overtime was observed for the intermediate vector dose
(4,0E + 11 GC/ml): from 56% at 4 weeks to 86% at 8 weeks;
and for the highest vector dose (8,0E + 11 GC/ml): from
73% at 4 weeks to 86% at 8 weeks. In contrast, delivery of
the rAAV2/7-eGFP in the SN of mice did not cause any
neurodegeneration in the STR (Figure 3B, E). Here again,
the neurodegenerative effect became stronger when the
viral titer increased.
We also compared WTand mutant A53T α-synuclein in
their potency to induce dopaminergic neuron loss over
time. Similar to the trends observed in Figure 2, the nigral
dopaminergic cell death caused by the delivery of A53T
α-synuclein was progressive over time and slightly en-
hanced, although not significantly different, when com-
pared to the WT α-synuclein vector at the same vector
dose. The dopaminergic cell loss in the SN varied from
51% at 4 weeks after injection to 59% at 8 weeks (com-
pared to 45% at 4 weeks and 50% at 8 weeks for WT
α-synuclein). As for the STR, 57% of the TH-positive
volume was lost at 4 weeks post-injection and 91% at
8 weeks (compared to 56% at 4 weeks and 86% at 8 weeks
for WT α-synuclein).
rAAV2/7 vector-mediated overexpression of α-synuclein
in mouse SN induces progressive phosphorylation of
α-synuclein at serine 129
Previous studies have shown that approximately 90% of the
α-synuclein accumulated in the LBs is phosphorylated at
serine residue at position 129 (P-S129) [30,31]. Therefore,
it is considered a marker of α-synuclein neuropathology
[49]. In order to further characterize the neuropathology
induced by the overexpression of α-synuclein in mouse
SN, we performed immunohistochemical stainings for
P-S129 α-synuclein (Figure 4A). Overall, we observed a net
increase over time in the number of P-S129 α-synuclein-
positive cells after injection of either rAAV2/7-α-synuclein
WT or A53T viral vectors while the contralateral side
showed no apparent immunoreactivity. A maximum of
P-S129 α-synuclein-positive cells was reached at 4 weeks
post-injection by WT α-synuclein vector delivered at 4,
0E + 11 or 8,0E + 11 GC/ml (Figure 4B). At 8 weeks after
injection, the number of positive cells at the intermediate
dose remained invariable, while a trend to a decrease was
observed for the highest dose, suggesting that the vast
cell loss observed at this time point affects the P-S129
α-synuclein counts. For the lowest α-synuclein vector dose
(2,6E + 11 GC/ml), a more moderate and delayed increase
in the number of nigral P-S129 α-synuclein-positive cells
was observed over time, in accordance with the lower rate
of neurodegeneration achieved by this dose. Interestingly,
the A53T α-synuclein condition exhibited a somewhat
lower number of nigral P-S129 α-synuclein-positive cells
at 5 days and 4 weeks when compared to the WT α-
synuclein viral vector.
Figure 3 α-Synuclein overexpression leads to progressive dose-dependent dopaminergic cell death in mouse SN and STR.
(A-B) Immunohistochemical stainings for TH in the (A) SN and in the (B) STR of mice injected with 3 different WT α-synuclein vector doses and a
unique eGFP or A53T α-synuclein vector dose show that overexpression of α-synuclein induces a progressive and dose-dependent TH cell loss
over time. Overexpression of A53T α-synuclein triggers a comparable loss to WT α-synuclein at the same vector dose. Note the absence of
dopaminergic neurodegeneration in the contralateral side at 8 weeks post-injection when cell loss was maximal. Scale bar (A) = 250 μm and
(B) = 500 μm. N-inj: non-injected side. (C-D) Stereological quantification of the number of TH-positive neurons in the SN of the (C) injected side
and (D) non-injected side after 5 days, 4 weeks and 8 weeks. (E) Stereological quantification of the TH-positive volume in the STR of the injected
side at 5 days, 4 weeks and 8 weeks post-injection. Asterisks (*) represent significant decrease respective to eGFP, unless specified otherwise.
Dagger (‡) depicts significant decrease respective to 4,0E + 11 GC/ml WT/A53T. 5 days 8,0E + 11 GC/ml eGFP and 4,0E + 11 GC/ml WT/A53T: n = 3;
5 days 2,6/8,0E + 11 GC/ml WT: n = 4; 4 weeks: n = 4; 8 weeks: n = 4.
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clein-positive cells in the SN by determining the ratio
between the number of P-S129 α-synuclein-positive cells
(Figure 4B) and the total number of α-synuclein-positive
cells (Figure 2F) in the SN. For all vector doses, we ob-
served a progressive increase over time in the percentage
of P-S129 α-synuclein-positive cells in the SN (Figure 4C).
Once more, we noted a dose-dependency effect given that
the increase in the percentage of P-S129 α-synuclein-positive cells was significantly different from low to high
vector dose at both 4 and 8 weeks after injection.
rAAV2/7 vector-mediated overexpression of WT or A53T
α-synuclein induces a progressive expression and
accumulation of human α-synuclein
To examine in more detail the nature and solubility of the
different α-synuclein species induced by viral vector
delivery, rAAV2/7 vectors encoding WT or A53T α-
Figure 4 Phosphorylation of α-synuclein at S129 increases over time in a dose-dependent manner after rAAV2/7-α-synuclein delivery.
(A) Representative images of P-S129 α-synuclein expression in the SN of mice injected with 3 different WT α-synuclein vector doses and a unique
A53T α-synuclein vector dose show that overexpression of WT α-synuclein induces a progressive and dose-dependent increase over time in P-S129
α-synuclein. Lack of immunoreactivity in the contralateral SN at 8 weeks after injection when expression was maximal. Right panels are magnifications
of the overview (left panels). Scale bars = 200 μm. (B) Stereological quantification of the number of P-S129 α-synuclein positive cells in the injected SN
after 5 days, 4 weeks and 8 weeks. (C) Percentage of P-S129 α-synuclein positive cells in the SN at 5 days, 4 weeks and 8 weeks post-injection. Asterisks
(*) depict significant increase respective to 5 days, unless specified otherwise. 5 days 4,0E + 11 GC/ml WT/A53T: n = 3; 5 days 2,6/8,0E + 11 GC/ml
WT: n = 4; 4 weeks: n = 4; 8 weeks: n = 4.
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SN at the unique vector titer of 4,0E + 11 GC/ml. To
separate most soluble from insoluble proteins, nigral
tissues were sequentially extracted using buffers with
different salt and detergent concentration, followed by
intermittent ultracentrifugation steps [46].
Samples were analyzed on Western blot in order to
identify changes in the solubility of human α-synuclein
encoded by the rAAV2/7-α-synuclein vector. We de-
tected an up-regulation of α-synuclein using both an
antibody recognizing mouse and human α-synuclein
(Syn1, aa 91–96) and a human-specific antibody (15G7,
aa 116–131). We observed a significant increase in soluble
human α-synuclein at 4 weeks after injection (~14 kDa) in
the cytoplasmic (TBS soluble) fraction for both WT and
A53T viral vectors (Figure 5A-B). Coherently, detergent-
insoluble α-synuclein detected in the Urea soluble fraction
was also markedly increased over time for both WT and
A53T viral vectors (Figure 5C-D). In the two isolated frac-
tions, human α-synuclein was undetectable in all immu-
noblots of the rAAV2/7-eGFP control vector at 4 weeks
time point (Figure 5A, C).Additionally, in the Urea soluble fraction, we observed
an increase in P-S129 α-synuclein between 5 days and
2 weeks for both α-synuclein vectors, although the in-
crease was more pronounced in the WT condition,
which is in agreement with our immunohistochemical
data (Figure 5C-D).
Motor behaviour impairments induced by rAAV2/7
vector-mediated overexpression of α-synuclein in
mouse SN
Finally, we wondered whether the progressive dopami-
nergic cell death triggered by the overexpression of
α-synuclein in the SN would affect the motor behaviour of
the mice. We first evaluated the performance of the mice
in the cylinder test. Somewhat surprisingly, no significant
differences between left and right forelimb use were de-
tected up to 8 weeks after injection (Figure 6A). Therefore
we decided to retest the animals at a later time point. At
12 weeks after injection, a small but significant decrease
in the use of the forelimb contralateral to the lesion
was observed with the medium dose of α-synuclein
(Figure 6A). However, since disturbances in behaviour
Figure 5 Soluble and insoluble α-synuclein levels increase over time upon delivery of rAAV2/7-α-synuclein WT or A53T. (A) Western
blot and (B) quantitative analysis (n = 3) of soluble α-synuclein in the cytoplasmic (TBS soluble) fraction of SN mouse lysates injected with rAAV2/
7-eGFP (4 weeks time point) or rAAV2/7-α-synuclein WT or A53T (5 days, 2 weeks and 4 weeks time points). (C) Immunoblotting and (D) quantification
(n = 3) of phosphorylated and detergent-insoluble α-synuclein in the Urea soluble fraction of injected mouse nigral homogenates. For detection,
immunoblots for α-synuclein were performed using a panel of different antibodies against: mouse and human α-synuclein (Syn1), specific human
α-synuclein (15G7) and P-S129 α-synuclein. GAPDH and β-actin serve as internal loading control in the TBS and Urea fractions, respectively.
Oliveras-Salvá et al. Molecular Neurodegeneration 2013, 8:44 Page 10 of 14
http://www.molecularneurodegeneration.com/content/8/1/44were clearly visible from the video-recordings, we used
two other motor tests. In the rotarod test executed at
14 weeks after injection, both α-synuclein groups, mid
and high dose, performed significantly worse than the
eGFP control group (Figure 6B). Similarly, in the open
field test carried out at 15 weeks after injection, both
rAAV2/7-α-synuclein injected groups of mice walked over
a considerably reduced distance compared to the eGFP
control group (Figure 6C).
Discussion
The goal of the current study was to develop a robust
mouse model that displays the most relevant neuropatho-
logical hallmarks of PD based on the targeted viral vector
delivery of α-synuclein to the SN. We showed that
rAAV2/7 vector-mediated overexpression of either WT or
mutant A53T α-synuclein results in an overt degeneration
of the nigral dopaminergic neurons concomitant with thedevelopment of motor impairments and the formation of
cytoplasmic α-synuclein inclusion bodies in a particularly
short time frame.
The identification of α-synuclein as a key factor in
idiopathic and inherited PD has impelled the develop-
ment of new mouse models overexpressing α-synuclein
over the last decade. However, transgenic mouse lines
have failed to reproduce convincingly a meaningful pro-
gressive dopaminergic neurodegeneration in the SN [12].
In contrast, local delivery of viral vectors overexpressing
α-synuclein in rat and non-human primate brains leads to
gradual nigral dopaminergic neuron loss, which is in ge-
neral more prominent with rAAV vectors compared to
lentiviral vectors [50]. However, the rAAV vector-based
mouse models published to date exhibit no or limited
dopaminergic cell loss with a maximum of 20 to 35% bet-
ween 2 and 6 months post-injection [33-38]. Moreover,
these mouse models do not display striatal dopaminergic
Figure 6 rAAV2/7 vector-mediated α-synuclein overexpression in mouse SN leads to motor behaviour impairments. (A) Performance in
the cylinder test of rAAV2/7-eGFP and rAAV2/7-α-synuclein WT mice at 1 week, 4 weeks, 8 weeks and 12 weeks after injection. No asymmetry in
forepaw use was detected up to 8 weeks. At 12 weeks after injection, a significantly reduced use of the contralateral forepaw was observed for
the mid dose of α-synuclein vector. (B) The rotarod test performed at 14 weeks after injection showed a significant reduction in average time on
the rotating rod for both rAAV2/7-α-synuclein doses. (C) A significant decline in the walking distance was observed for the two α-synuclein doses
tested in the open field at 15 weeks after injection. For all tests: 8,0E + 11 GC/ml eGFP/WT and 4,0E + 11 GC/ml WT: n = 10.
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viral vector-mediated overexpression of WT or mutant
A30P α-synuclein in mouse SN induces up to 25% dopa-
minergic neurodegeneration at 10 to 12 months after
injection [16]. The long time scope needed to achieve
a substantial neurodegeneration differs from our new
mouse model developed in the present study in the type
of viral vector used. rAAV vectors are more efficient than
lentiviral vectors in transducing the dopaminergic neurons
of the SN because of their high titers and neuronal tro-
pism. In this regard, it is remarkable that a very recent
study using lentiviral vectors for the overexpression of
α-synuclein in mouse SN has reported around 60% dopa-
minergic cell loss after 45 days for the A30P, A53T and
E46K mutant and about 25% for WT α-synuclein [51].
The experience with viral vector-based rat models has
proved that transduction efficiency and transgene ex-
pression levels greatly determine the degree of nigral
neuron degeneration and the time span over which this
occurs [52,53]. Consequently, we have previouslyoptimized large-scale and flexible manufacturing pro-
cesses for rAAV vector production [54]. In addition, we
have shown that our improved rAAV vectors efficiently
transduce nigral dopaminergic neurons [19]. Based on
this comparative study, we selected the rAAV2/7 sero-
type for overexpression of α-synuclein because it com-
bines high transgene expression levels and high
transduction efficiency of the dopaminergic neurons
in vivo. We optimized a rat model of PD based on
rAAV2/7 vector-mediated overexpression of A53T α-
synuclein in the SN. Rats receiving a vector dose of 3,
0E + 11 GC/ml displayed 80% loss of the nigral dopa-
minergic neurons at 4 weeks post-injection (Van der
Perren et al., submitted). In parallel to that study, we
have shown here that targeted nigral overexpression of
WT α-synuclein by means of a rAAV2/7 vector induces
up to 82% dopaminergic cell death in mouse SN within
2 months. The extent of cell loss for the whole popula-
tion of α-synuclein overexpressing cells (maximum of
about 50% at 8 weeks) is lower than the loss of TH-
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which suggests that the dopaminergic neurons are more
vulnerable to α-synuclein neurotoxicity.
α-Synuclein pathology is the second major neuropatho-
logical feature of PD after the progressive dopaminergic
cell loss. Therefore, it is an essential characteristic to repli-
cate in a relevant animal model of PD. However, the rAAV
vector-based mouse models for α-synuclein reported in
literature until now do not present detectable α-synu-
clein-positive aggregates as far as 6 months post-injection
[35]. Other studies with rAAV overexpression of α-
synuclein in rats and non-human primates demonstrate the
presence of α-synuclein-rich inclusions [23-25,28,29,55].
Both our new rAAV2/7-based and previous lentiviral
vector-based mouse models for α-synuclein exhibited
visible inclusions abundant in α-synuclein protein in the
surviving neurons [16,17]. In addition, we here demon-
strated increasing levels of insoluble transgenic α-synu-
clein over time. We also observed a gradual increase in
the percentage of P-S129 α-synuclein-positive cells in
the SN, supporting the progressive development of
α-synuclein neuropathology and the presence of LB-like
α-synuclein-rich inclusions.
Another objective of the current study was to test a
dose dependency of viral vector-mediated overexpres-
sion of α-synuclein. For this approach, we used 3 dif-
ferent doses of WT α-synuclein vector in mouse SN that
led to a dose-dependent and gradual neurodegeneration
over time. With our lowest vector dose, we achieved a
similar degree of dopaminergic cell death as previous
studies in mice [33,35,37], while the highest dose tested
induced extensive (57%) nigral dopaminergic neurode-
generation in just 4 weeks. To our knowledge, this is the
first dose dependence study of viral vector overexpres-
sion of α-synuclein carried out in mouse brain. Similar
comparative studies have been performed in rats, which
also reported differences in rates of neurodegeneration
in the SN and in behavioural performance based on the
viral vector titer used [28,52,53,56].
In the present study, we investigated the behavioural
performance of the mice at two different doses of WT
α-synuclein viral vector. Somewhat surprisingly, the cylin-
der test showed only a minor asymmetric forepaw use at
12 weeks after injection compared to the eGFP control
group, while all previous time points did not reveal any
impairment. In an independent study, we also did not ob-
serve impairments in spontaneous forelimb use in mice
with ~50% TH cell loss achieved at 4 weeks post-injection
by overexpression of rAAV2/7-α-synuclein WT in mouse
SN (Oliveras-Salvá et al., submitted). These observations
are in contrast with own previous results obtained in rats
where the same level of dopaminergic neuron loss resulted
in a clear decrease in contralateral forepaw use (Van der
Perren et al., submitted). However, careful observation ofthe mice in the cylinder test revealed a general behavioural
impairment and slowness of movement. Therefore, we
also performed the rotarod and open field tests which
showed pronounced motor behaviour deficits in both
α-synuclein groups at a later time point. These impair-
ments can be ascribed to the extensive dopaminergic cell
death obtained in mouse SN after the injection of the
rAAV2/7-α-synuclein vector.
Finally, we evaluated whether the overexpression of
the A53T clinical mutant triggered a substantially dif-
ferent degeneration of the dopaminergic cells in the SN
compared to the WT α-synuclein. Overall, the neurode-
generation induced over time by the A53T α-synuclein
viral vector in the SN and the STR was slightly enhanced
when compared to the WT α-synuclein vector, although
the difference was never significant. To date, there is
no consensus in literature about the neurotoxicity
of mutant A53T α-synuclein in comparison to WT
α-synuclein in vivo. This is partly due to the scarcity of
parallel comparative studies in which WT and A53T
α-synuclein are investigated under the same conditions.
Other studies have compared human WT and mutant
A53T α-synuclein encoded by viral vectors in other
species. On the one hand, Eslamboli and colleagues
reported that the A53T variant induces a significantly
enhanced dopaminergic neuron loss when compared to
WT at one year after rAAV nigral injection in non-
human primate brain and, correlating with the degree of
induced cell death, two different microglia activation
profiles were reported [55,57]. On the other hand, other
studies performed in rats and non-human primates
showed that rAAV vector-based delivery of WT and
A53T α-synuclein induces a comparable neurodegenera-
tive process, as well as aggregate formation [23,29,56].
Our findings in the present study are in agreement with
these latter publications. In mice, we have previously re-
ported that overexpression of WT and A30P α-synuclein
by means of lentiviral vectors induces a similar rate in
dopaminergic cell death and comparable α-synuclein
pathology in a long-term study of 12 months [16].
In our hands, the overexpression levels rather than
the clinical mutation determine the neuropathological
changes in our model.
Conclusions
To conclude, we have developed a robust α-synuclein
mouse model by means of rAAV2/7-vector delivery
which recapitulates several indispensable features of a
PD animal model: motor deficits, robust and progressive
nigral dopaminergic neuron loss over time and the pres-
ence of α-synuclein-rich inclusions in the surviving cell
bodies. An animal model that recapitulates the main
hallmarks of the disease is a powerful tool to elucidate
the mechanisms at the origin of the disease and to find
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and knockout mouse lines provides the possibility to in-
vestigate the molecular pathways leading to PD and to
study the effect of other PD-related genes on α-synuclein-
induced cell death. Moreover, viral vector-based animal
models of PD, such as the one described here, constitute a
rapid platform for the screening of new potential therapies
aiming at halting or modifying the progression of this
devastating neurodegenerative disorder.
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